Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 3 (March)

1. Risk factors for benign serous and mucinous epithelial ovarian tumors.
   Obstet Gynecol, 109(3): 647-54. [Abstract] [Full-text]
2. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.
   Obstet Gynecol, 109(3): 641-6. [Abstract] [Full-text]
3. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
   Obstet Gynecol, 109(3): 597-607. [Abstract] [Full-text]
4. Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer.
   J Genet Couns, 16(2): 211-22. [Abstract] [Full-text]
5. Increasing utilization of cancer genetic counseling services using a patient navigator model.
   J Genet Couns, 16(2): 171-7. [Abstract] [Full-text]
6. Dietary fiber intake and ovarian cancer risk: a prospective cohort study.
   Cancer Causes Control, 18(3): 335-41. [Abstract] [Full-text]
7. Deletion of the intracellular domain of coxsackie and adenovirus receptor (CAR) enhances the expression of itself and boosts the efficiency of current adenovirus-mediated gene therapy in ovarian cancer cell lines in vitro.
   Cancer Lett, 248(2): 299-307. [Abstract] [Full-text]
8. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.
   Int J Cancer, 120(9): 1863-73. [Abstract] [Full-text]
9. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
   Clin Exp Immunol, 148(1): 136-45. [Abstract] [Full-text]
10. Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells.
    Life Sci, 80(15): 1403-8. [Abstract] [Full-text]
11. Evaluation of zinc status in whole blood and scalp hair of female cancer patients.
    Clin Chim Acta, 379(1): 66-70. [Abstract] [Full-text]
12. Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma.
    Diagn Cytopathol, 35(4): 193-7. [Abstract] [Full-text]
13. Diet and risk of ovarian cancer in the California Teachers Study cohort.
    Am J Epidemiol, 165(7): 802-13. [Abstract] [Full-text]
14. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study.
    Fertil Steril, 87(3): 591-6. [Abstract] [Full-text]
15. A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate.
    Cancer Res, 67(6): 2791-9. [Abstract] [Full-text]
16. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Cancer Res, 67(6): 2773-82. [Abstract] [Full-text]
17. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Cancer Res, 67(6): 2408-13. [Abstract] [Full-text]
18. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
    Am J Reprod Immunol, 57(4): 243-9. [Abstract] [Full-text]
19. Metastatic carcinoma of the ovary presenting as zosteriform lesions.
    Arch Iran Med, 10(2): 250-2. [Abstract] [Full-text]
20. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
    Life Sci, 80(16): 1458-65. [Abstract] [Full-text]
21. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Hum Pathol, 38(4): 607-13. [Abstract] [Full-text]
22. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.
    Biochem Biophys Res Commun, 356(1): 72-7. [Abstract] [Full-text]
23. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Cancer Chemother Pharmacol, 59(6): 711-23. [Abstract] [Full-text]
24. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
    Virchows Arch, 450(4): 387-95. [Abstract] [Full-text]
25. Mature and immature teratomas: results of the first paediatric Italian study.
    Pediatr Surg Int, 23(4): 315-22. [Abstract] [Full-text]
26. Inhibin as a diagnostic marker for ovarian cancer.
    Cancer Lett, 249(1): 14-7. [Abstract] [Full-text]
27. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Gynecol Oncol, 105(1): 238-43. [Abstract] [Full-text]
28. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity.
    Life Sci, 80(18): 1641-9. [Abstract] [Full-text]
29. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
    J Immunol Methods, 321(1): 86-93. [Abstract] [Full-text]
30. Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report.
    Gynecol Oncol, 105(1): 244-7. [Abstract] [Full-text]
31. Advanced malignant rhabdoid tumor of the ovary effectively responding to chemotherapy: a case report and review of the literature.
    Gynecol Oncol, 105(1): 261-5. [Abstract] [Full-text]
32. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Gynecol Oncol, 105(1): 31-44. [Abstract] [Full-text]
33. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Gynecol Oncol, 105(1): 194-8. [Abstract] [Full-text]
34. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Gynecol Oncol, 105(1): 211-7. [Abstract] [Full-text]
35. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Gynecol Oncol, 105(1): 205-10. [Abstract] [Full-text]
36. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells.
    Gynecol Oncol, 105(1): 23-30. [Abstract] [Full-text]
37. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Gynecol Oncol, 105(1): 66-73. [Abstract] [Full-text]
38. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.
    Gynecol Oncol, 105(1): 145-9. [Abstract] [Full-text]
39. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Gynecol Oncol, 105(1): 223-7. [Abstract] [Full-text]
40. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Gynecol Oncol, 105(1): 17-22. [Abstract] [Full-text]
41. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.
    Gynecol Oncol, 105(1): 166-71. [Abstract] [Full-text]
42. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
    Gynecol Oncol, 105(1): 104-12. [Abstract] [Full-text]
43. Prognostic significance of iNOS in epithelial ovarian cancer.
    Gynecol Oncol, 105(1): 97-103. [Abstract] [Full-text]
44. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Gynecol Oncol, 105(1): 113-21. [Abstract] [Full-text]
45. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
    Gynecol Oncol, 105(1): 90-6. [Abstract] [Full-text]
46. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Gynecol Oncol, 105(1): 122-31. [Abstract] [Full-text]
47. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
    Gynecol Oncol, 105(1): 132-7. [Abstract] [Full-text]
48. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
    Gynecol Oncol, 105(1): 84-9. [Abstract] [Full-text]
49. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome.
    Eur J Obstet Gynecol Reprod Biol, 131(2): 203-8. [Abstract] [Full-text]
50. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider.
    CMAJ, 176(7): 941-7. [Abstract] [Full-text]
51. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Cancer, 109(7): 1323-30. [Abstract] [Full-text]
52. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
    Ann Oncol, 18(4): 716-21. [Abstract] [Full-text]
53. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.
    Ann Oncol, 18(4): 709-15. [Abstract] [Full-text]
54. A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.
    Am J Pathol, 170(4): 1325-36. [Abstract] [Full-text]
55. Methylation profile in benign, borderline and malignant ovarian tumors.
    J Cancer Res Clin Oncol, 133(5): 331-41. [Abstract] [Full-text]
56. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas.
    Oncogene, 26(14): 2136-40. [Abstract] [Full-text]
57. Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling.
    Genet Test, 11(1): 45-54. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.